Personalised circulating tumour DNA could have the potential to be the biomarker routinely used by oncologists treating patients with colorectal cancer, two new studies suggest.

The “exciting technology” may eventually be used to predict who will have recurrence after surgery; who should have adjuvant chemotherapy; and in assessing whether therapy has worked, say the authors of an editorial in JAMA Oncology discussing both pieces of research.